GE Healthcare News

1. Precision NanoSystems And Aurora Vaccines Join Forces To Accelerate The Development Of Vaccine Candidate For Hepatitis C Virus 6/23/2023

   Global leader in non-viral delivery of genomic medicines, Precision NanoSystems (PNI), entered into a strategic collaboration agreement with Aurora Vaccines to accelerate the development and manufacture of its Hepatitis C vaccine candidate. PNI will share its expertise in the development of the RNA payload platform and its proprietary lipid nanoparticle (LNP) platforms to help bring Aurora’s RNA-LNP vaccine candidate for the prevention of Hepatitis C virus (HCV) infection to a Phase I clinical trial.